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1. Introduction
Nanomedicine is an emerging field that has caught the interest of many medical 
scientists and chemists due to its unique characteristics that open the door wide for 
several unique applications that might lead to solving many problems that were found 
difficult to tackle in medicine. Nanomedicine has opened a new category of medicines 
called nanomedicines where the medicine is reduced to the nanoscale size, hoping to 
enhance its physicochemical properties. The chapter summarizes the nanomedicines 
that have been approved by the Food and Drug Administration (FDA) or European 
Medicines Agency (EMA) and the nanomedicines whose clinical trials based on 
previously published review articles by Anselmo and Mitragotri are ongoing [1, 2].
To gain insight to current trends in nanomedicine research and the most success-
ful types of nanomedicines in the market, the approved nanomedicines are pre-
sented in Figure 1. The number of approved nanomedicine products is 29 till 2019 
[1]. Liposomes represented 44.8% (13 products). Inorganic nanoparticles ranked 
second with 41.4% (12 products). Other nanoparticles (polymeric and protein) 
have only 4 products (13.8%). These findings are very interesting as liposomes are 
one of the oldest nanomedicines. This opens an argument about the challenges in 
nanomedicine translation as a new platform requires further investigations to prove 
its activity and safety. On the other hand, cancer nanotherapeutics is ranked first 
with 10 products in the market, followed by iron-replacement therapies with 8 
products. Also, it is worth to mention that imaging agents (six marketed products) 
are ranked in third place, especially the inorganic nanoparticles (three products).
Moreover, nanomedicines, currently undergoing clinical trials, are presented in 
Figure 2. The number of products under clinical trials is 47 till 2019 [1], where lipo-
somes represented 61.7% (29 products) and micelles ranked second with 19.15% 
(9 products). Other nanoparticles have only nine products (19.15%). Also, these 
findings are similar to approved nanomedicine, where liposomes are the most used 
nanomedicine. On the other hand, 39 products are dedicated for cancer treatment. 
It is worth to mention that 10 products out of the 39 products are loaded with gene 
therapy and not chemotherapeutic agents.
Generally, the total number of nanomedicines in the market or in clinical 
trial are 76 products, where liposome formulations were the most used delivery 
system with 55.26% (42 products), followed by inorganic nanoparticles with 
21% (16 products) as presented in Figure 3. According to the World Health 
Organization in 2015, the first leading cause of death in around 50% of countries 
is cancer [3]. According to the International Agency for Research on Cancer 
report that published in 2018 on the global burden of cancer, there are 18.1 million 
cancer cases and 9.6 million cancer deaths in 2018 [3]. These reports inspired the 
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Figure 3. 
Total number of nanomedicines approved and under clinical trials (therapeutic and diagnostic).
Figure 2. 
Nanomedicine currently undergoing clinical trials for therapy and diagnostic.
Figure 1. 
Clinically approved nanomedicine for therapy and diagnostic.
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pharmaceutical industry to invest in this market. As mentioned previously, there 
are only 10 nanomedicine products out of 29 products available in the market to 
treat cancer, while there are 39 products out of 47 products for cancer treatment. 
This number of clinical trials for cancer is mainly derived by the 15 years of support 
by the US National Cancer Institute through the Centers of Cancer Nanotechnology 
Excellence (CCNEs) [4].
2. Types of nanomedicines
Nanomedicines are mainly classified into two classes, either inorganic nanopar-
ticles such as gold, silica, and iron oxide or organic nanoparticles such as polymeric, 
liposomes, and micelles (Figure 4). These nanoparticles are mostly used for 
therapeutic and diagnostic nanoparticles. Inorganic nanoparticles have been used 
for a variety of applications including lymph node imaging, hyperthermia, and 
anemia treatment. Some of them have successfully gone through preclinical studies 
and clinic trials. Along with inorganic nanoparticles, organic-based nanoparticles 
have successfully reached the clinical phase and currently reached the market for 
different applications like vaccination, microbial infection, and cancer.
2.1 Liposome-based nanomedicines
Liposome-based nanomedicine is a type of drug formulation where a drug is 
encapsulated inside the phospholipid bilayer structure to enhance its bioavailability 
and therapeutic activity. Liposome formulations are one of the oldest nanomedi-
cines with a well-established technique. Many research efforts were focused on 
using liposomes to encapsulate several cargos like small molecules such as doxo-
rubicin, nucleic acid such as RNAs, and biological molecules such as vaccines for 
hepatitis A virus. Furthermore, administration of the liposomes without an encap-
sulated drug is also a possibility if the liposome subunits have a certain therapeutic 
effect such as sphingomyelin and cholesterol. PEGylation is an option to consider 
while using liposomes due to its importance in adding stealth to the delivery system. 
Most of the approved liposome-based nanomedicines are used for the treatment 
of cancer diseases. They take a large place in research as 10 out of the 29 approved 
nanomedicines are liposome-based.
Figure 4. 
Clinically approved and investigated nanomedicines including organic nanoparticles and inorganic 
nanoparticles.
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2.2 Lipid-based nanomedicines
Lipid nanosystems including nanoemulsions and solid lipid-based nanoparticles 
are another form of nanomedicine, which are usually used to encapsulate hydropho-
bic cargos to improve permeation and control release profile. Usually, a surfactant 
is used to ensure a uniform dispersion. Lipid nanomedicine can also encapsulate 
some gene therapeutics such as siRNA or contrast agents used for imaging such as 
F-butane. Generally, lipid nanomedicine can improve the pharmacological effect 
by enhancing drug accumulation in targeted tissues beside its biocompatibility. 
However, there are several drawbacks like rapid clearance due to reticuloendothelial 
system (RES) uptake and some limitations for administration routes and challenges 
regarding system stability [5, 6]. Unlike liposomal-based nanomedicines, lipid-based 
nanomedicines are not limited for cancer diseases only. Some of the diseases that 
are treated by lipid-based nanomedicines are amyloidosis, hepatitis B, and hepatic 
fibrosis. Furthermore, several types of nanoemulsion were loaded with drugs like 
simvastatin, cinnarizine, coenzyme Q10, and cyclosporine, which used as antihy-
perlipidemia, antihistaminic, antioxidant, and immunosuppressants, respectively.
2.3 Albumin-based nanomedicines
Albumin-based nanomedicines are another form of nanosystems, where 
albumin, especially human serum albumin (protein), is used as a carrier. Albumin 
nanosystems can be loaded with different cargos via a simple self-assembly pro-
cedure of albumin in aqueous solution with simple crosslinking step. The main 
advantage of albumin is biocompatibility. Despite that, only 2 out of the 29 listed 
approved nanomedicines and 2 out of the 65 nanomedicines under clinical trials 
are albumin-based. It is currently used in imaging and delivering drugs that treat 
cancer diseases.
2.4 Micelle-based nanomedicines
Micelles are self-assembled nanosystem by amphiphilic molecules that have a 
hydrophilic part and a hydrophobic one. They have several advantages like high 
permeability and solubility, which improve drug bioavailability. However, they still 
have some drawbacks like insufficient control to drug release and cytotoxicity due 
to amphiphilic molecule use, which interact with cell membrane [5, 7]. Although 
several reports used block copolymeric micelles to reduce clearance and increase 
bioavailability of chemotherapeutic agents and other types of drugs, there are no 
approved micelle-based nanomedicines. However, there are currently nine micelle-
based nanomedicines undergoing clinical trials. Majority of them are used for 
cancer treatment.
2.5 Polymeric-based nanomedicines
Polymeric nanoparticles are one of the most commonly used nanosystems for 
drug delivery. Several polymers have been used like ethyl cellulose, poly(lactic-
co-glycolic acid), polylactic acid, cyclodextrin, alginate, and chitosan. Depending 
on the nature of the polymer, either hydrophilic or hydrophobic, there are several 
techniques that have been used to prepare polymeric nanoparticles. Several 
advantages like relative stability and prolonged duration of action make polymeric 
nanoparticles a promising platform for the market. However, there are no marketed 
products based on polymeric nanoparticles. Only three products are currently on 
clinical trials for cancer.
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2.6 Inorganic-based nanomedicines
Inorganic-based nanomedicines have several subtypes. Due to degradability and 
biocompatibility issues, few types have been used for therapeutic purpose, while 
other types for diagnostic purpose like imaging agents. One of these subtypes are 
metal oxide nanoparticles such as hafnium oxide nanoparticles which enhance 
tumor cell death via electron production through their stimulation with external 
radiation. Another subtype is in the form of colloids such as iron dextran colloids, 
iron gluconate colloid, and other similar derivatives that are usually used for the 
treatment of iron-deficiency anemia. The last subtype mentioned is iron−/silica−/
gold-based nanomedicines, either as nanoparticles with drugs arranged on the 
surface for the treatment of cancer or as nanoshells/nanoparticles used for thermal 
ablation of tumors. There are 12 products in the market that belong to this type. 
Eight products used iron-replacement therapies. On the other hand, four products 
are currently on clinical trials for treating cancer.
3. Nanomedicines pharmacokinetic and regulations
The pharmacokinetic parameters of nanomedicines are similar to free drugs with 
addition phase after drug administration, which is the liberation phase beside the 
standard absorption, distribution, metabolism, and excretion (ADME). This new 
phase is controlled by particle nature, size, shape, and surface properties. It is worth 
to mention that particle size is very important for absorption and elimination. 
Particles with particle size <5 nm is easily excreted from the kidney, while larger 
particle size could be eliminated by the liver or engulfed by mononuclear-phagocyte 
system. Moreover, particle size and shape can affect particle accumulation in 
targeted tissues like ellipsoidal shape that has better distribution and retention in 
tumor tissue than spherical one. Surface modification of nanoparticles can affect 
particle uptake and elimination. Many nanoparticles are coated for active and pas-
sive targeting. Passive targeting is a non-specific retention in target tissue like solid 
cancer tissue by enhanced permeability and retention mechanism. Active targeting 
is the selective uptake of nanomedicine by specific cells. Target moieties could be 
protein, antibody, or small molecule selective to specific tissues or cells. This mecha-
nism is mainly controlled by homing to overexpressed cell surface receptors.
The Food and Drug Administration classified nanoscale materials to nanoma-
terials as “materials used in the manufacture of nanomedicine” or nanomedicine 
as “final products,” The FDA approved 51 nanomedicines by the year 2016, 40% of 
which were in clinical trials between 2014 and 2016. According to the FDA evaluation 
of nanomedicines, it includes the physicochemical properties, followed by pharma-
cokinetics evaluation of nanomedicines. The pharmacokinetics evaluation includes 
(1) rate and amount of absorption, (2) retention in circulation, (3) half-life and com-
plete elimination, (4) bioavailability differences, (5) distribution or accumulation to 
the body or specific tissue for active targeting, (6) decomposition or metabolism, (7) 
elimination, and (8) toxicity assessment of nanomedicines. On the other hand, the 
European Medicines Agency defined nanomedicines as “drugs composed of nano-
materials 1–100 nm in size, and these are classified into liposomes, nanoparticles, 
magnetic nanoparticles, gold NPs, quantum dots, dendrimers, polymeric micelles, 
viral and non-viral vectors, carbon nanotubes, and fullerenes.” EMA has approved 
eight commercially available nanomedicines as first-generation nanomedicines. 
Currently, there are 48 nanomedicines in clinical trials (Phases 1–3) in the EU. EMA 
evaluates the pharmacokinetics and pharmacodynamics of nanomedicines through 
investigation of their chemical composition and physicochemical properties [8].
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4. Approved application and indication of nanomedicine
4.1 Cancer nanoparticle medicines
Most pharmaceutical industries are focusing on developing new products for 
cancer as it is the first cause of death in 50% of the countries. Nanomedicine prod-
ucts have a good share in this market with many approved products to treat several 
types of cancer at various stages. Abraxane® is a famous albumin-particle bound 
paclitaxel nanomedicine loaded for advanced non-small cell lung cancer, metastatic 
breast cancer, and metastatic pancreatic cancer. Doxil®, the first approved nano-
medicine by the FDA in 1995, is a PEGylated liposome loaded with doxorubicin for 
ovarian cancer, HIV-associated Kaposi’s sarcoma, and multiple myeloma. Marqibo® 
is a liposomal vincristine for Philadelphia chromosome-negative acute lymphoblas-
tic leukemia. Hensify® is the recently approved nanomedicine for cancer in 2019 by 
the FDA. It is the hafnium oxide nanoparticles stimulated with external radiation 
to enhance tumor cell death via electron production for locally advanced squamous 
cell carcinoma. Most of the approved nanomedicines are non-PEGylated except 
Doxil and Onivyde, which is interesting as most reports have proven the importance 
of nanomedicine coating with PEG. Furthermore, all nanomedicine products do not 
have active target moiety. So, all of these products follow passive targeting approach 
without even stealth characteristics.
4.2 Iron-replacement nanoparticle therapies
Iron-replacement therapy to treat anemia is surprisingly another area for 
nanomedicine due to the significance of nanoscale iron-oxide colloid system in 
improving iron absorption to the body. The main advantage of iron-oxide nano-
medicine is replacing the injection of free iron with its associated toxicity. Most of 
these nanosystems are coated with either polysaccharide or polymer to reduce iron 
toxicity. CosmoFer® is the first approved iron dextran colloid by the FDA in 1996. 
Injectafer® is the most recent one in 2013 by the FDA, which is iron carboxymaltose 
colloid.
4.3 Nanoparticle/microparticle imaging agents
Another area for nanomedicine, especially the inorganic ones, is diagnostics, 
mainly imaging agents. Iron-oxide nanomedicines are also approved as contrasting 
agents for magnetic resonance imaging, which is used to generate contrasted images 
for different types of cancers. The magnetic property and small particle size allow 
the distribution of iron-oxide nanomedicine in tumor tissue, which provide a pre-
cise imaging of cancer borders. Additionally, perflutren is also used as ultrasound 
contrast agent in either lipid- or albumin-based nanomedicines. Phospholipid-
stabilized microbubble is another form of nanomedicine as ultrasound contrast 
agent, which is approved in 2001 by the EMA. Its main mechanism is encapsulating 
air bubbles, which act as reflectors for ultrasound.
4.4  Nanoparticles for vaccines, anesthetics, fungal treatments, and macular 
degeneration
Several clinical applications have been studied using nanomedicine. Diprivan® 
is the first FDA-approved nanomedicine in 1989 for anesthesia. Another field for 
nanomachine is vaccination with two products, which are Epaxal® for hepatitis A 
and Inflexal V® for influenza. Both vaccines are liposome-based nanomedicine due 
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to the similarity of liposome structure to cell structure. Another famous liposome 
product is AmBisome®, which is a liposome loaded with amphotericin B for treat-
ing systemic fungal infections with reduced toxicity. Abelcet® is another approved 
lipid-based nanomedicine loaded with amphotericin B. Finally, Visudyne® is a 
liposomal verteporfin for treatment of subfoveal choroidal neovascularization from 
age-related macular degeneration, pathologic, or ocular histoplasmosis.
5. Conclusion
Nanomedicines are currently in the middle of the road with great potentials but 
require many development considerations regarding assessment of physicochemical 
properties, pharmacokinetic properties, and pharmacodynamic applications. Based 
on the recent trends with 47 products in clinical trial phases, it is expected that 
within the next few years, more products will be available for several applications, 
especially cancer.
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